Advances in mesenchymal stem cell therapy for lupus nephritis

doi:10.4252/wjsc.v17.i8.104930

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (20)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=20

Aug 26, 2025 (publication date) through Aug 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Aug 26, 2025; 17(8): 104930
Published online Aug 26, 2025. doi: 10.4252/wjsc.v17.i8.104930

Advances in mesenchymal stem cell therapy for lupus nephritis

Lin Liu, Tapas Ranjan Behera, Qiao-Jun Wang, Quan-Quan Shen

Lin Liu, Qiao-Jun Wang, Quan-Quan Shen, Department of Nephrology, Urology & Nephrology Center, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China

Lin Liu, Life Sciences Institute, Zhejiang University, Hangzhou 310058, Zhejiang Province, China

Tapas Ranjan Behera, Department of Cancer Biology, Cleveland Clinic, Cleveland, OH 44195, United States

Quan-Quan Shen, Department of Nephrology, Zhejiang Provincial People’s Hospital Bijie Hospital, Bijie 551700, Guizhou Province, China

Author contributions: Liu L drafted the manuscript; Behera TR and Wang QJ performed the literature search; Behera TR and Shen QQ revised the manuscript; Shen QQ designed the research; all authors have read and approved the final manuscript.

Supported by Natural Science Foundation of Zhejiang Province, No. LY23H050005; and Zhejiang Medical Technology Project, No. 2020KY439, No. 2022RC009, No. 2024KY645, and No. 2024KY697.

Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Quan-Quan Shen, MD, Associate Professor, Department of Nephrology, Zhejiang Provincial People’s Hospital Bijie Hospital, No. 112 Guanghui Road, Bijie 551700, Guizhou Province, China; Department of Nephrology, Urology & Nephrology Center, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China. spring198457@sina.com

Received: January 7, 2025
Revised: April 5, 2025
Accepted: July 1, 2025
Published online: August 26, 2025
Processing time: 226 Days and 21.2 Hours

Core Tip

Core Tip: Lupus nephritis (LN) is one of the most common and serious complications of systemic lupus erythematosus. Mesenchymal stem cell (MSC) therapy has received extensive attention in LN. This article summarizes the sources of MSCs, the mechanisms of MSC therapy in LN treatment and the results of clinical trials. MSC therapy for LN shows great potential but still requires the support of large-scale clinical trials.